Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

European prescribing of new anticoagulants on the increase

Daiichi Sankyo-backed study shows doctors are turning to new drugs for VTE

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Santhera closer to filing for muscular dystrophy drug

Catena/Raxone slows loss of lung function in late stage trial

- PMLiVE

Drug to reverse Pradaxa effects starts pivotal trials

Potential antidote could give Boehringer edge over rivals in oral anticoagulant competition

- PMLiVE

UK pharma’s ‘controversial’ new pharmacist compliance rules

As the changes take effect CompliMed's Dr Rina Newton says they look to be a practical step forward

- PMLiVE

New technology can unlock revenue opportunities for pharma brands

Keep engaged with customers as new touchpoints emerge

- PMLiVE

Novartis appoints new comms chief

Michael Willi replaces Michele Galen

- PMLiVE

Hill+Knowlton Strategies creates EMEA division

Will be led by European president Lars Erik Grønntun

- PMLiVE

Novartis, Boehringer stake claims to combination COPD market

Includes combination follow-up to Spiriva

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

- PMLiVE

Gilead’s RSV drug clears mid-stage trial

Late-stage data demonstrates GS-5806 is effective in treating the infection

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links